Comparison of perioperative and subacute postoperative complications between LDR and HDR monotherapy brachytherapy for prostate cancer.

Acute toxicity Brachytherapy Cardiopulmonary toxicity High dose rate Interstitial Low dose rate Prostate cancer Subacute toxicity

Journal

Brachytherapy
ISSN: 1873-1449
Titre abrégé: Brachytherapy
Pays: United States
ID NLM: 101137600

Informations de publication

Date de publication:
25 Jul 2024
Historique:
received: 22 02 2024
revised: 30 05 2024
accepted: 01 06 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 26 7 2024
Statut: aheadofprint

Résumé

We aim to investigate perioperative and subacute postoperative complications in patients undergoing LDR or HDR monotherapy for prostate cancer. We hypothesize a low rate of complications, and a favorable toxicity profile in patients treated with HDR compared to LDR. A prospectively collected institutional database was queried for patients treated with HDR or LDR prostate monotherapy between 1998 and 2021. Toxicities were determined per CTCAE. Claims based billing codes were obtained to identify additional events. Events occurring within 4 months of treatment were defined as perioperative or subacute postoperative complications. 759 patients were identified, 446 received LDR with Overall toxicity rates support the safety of prostate brachytherapy. HDR monotherapy is associated with significantly less perioperative and subacute postoperative GU events when compared to LDR monotherapy. Cardiopulmonary events were equally rare in both groups.

Identifiants

pubmed: 39060143
pii: S1538-4721(24)00077-1
doi: 10.1016/j.brachy.2024.06.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Peter L Lee (PL)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: peter.lee@fccc.edu.

Karen Ruth (K)

Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA.

Douglas Y Lee (DY)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Mark A Hallman (MA)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

David Y T Chen (DYT)

Department of Urology, Fox Chase Cancer Center, Philadelphia, PA.

Jessica Karen Wong (JK)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Andres F Correa (AF)

Department of Urology, Fox Chase Cancer Center, Philadelphia, PA.

Iavor Veltchev (I)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Teh Lin (T)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Xiaoming Chen (X)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Joseph Panetta (J)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Alexander Kutikov (A)

Department of Urology, Fox Chase Cancer Center, Philadelphia, PA.

Eric M Horwitz (EM)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Classifications MeSH